Literature DB >> 11739438

Inflammatory cardiovascular risk markers in women with hypopituitarism.

G Sesmilo1, K K Miller, D Hayden, A Klibanski.   

Abstract

Patients with hypopituitarism have increased cardiovascular mortality. A high prevalence of conventional cardiovascular risk factors, including obesity, central fat distribution, insulin resistance, and dyslipidemia, have been described in these patients. The inflammatory markers C-reactive protein (CRP) and IL-6 are predictors of cardiovascular events, and high levels of CRP have been reported in men with hypopituitarism and GH deficiency. However, little is known about inflammatory cardiovascular risk markers in women with hypopituitarism. We therefore investigated whether inflammatory and traditional cardiovascular risk markers are elevated in women with hypopituitarism. Fifty-three women with hypopituitarism and 111 healthy control women were included in this cross-sectional study. Morning blood samples were drawn after an overnight fast. Serum was assayed for CRP, IL-6, glucose, insulin, IGF-I, triglycerides, total cholesterol, low density lipoprotein cholesterol, high density lipoprotein (HDL) cholesterol, lipoprotein(a), E2, total testosterone (total T) and free testosterone (free T), and dehydroepiandrosterone sulfate. IL-6 and CRP levels were higher in women with hypopituitarism than in healthy controls (P < 0.0001 for comparison between groups). In a multivariate model, CRP levels depended on hypopituitarism, body mass index (BMI), and estrogen use. There was an interaction between the effect of BMI and hypopituitarism on CRP levels, such that the importance of hypopituitarism in determining CRP levels disappeared at high BMIs. In a similar multivariate model, IL-6 levels depended on hypopituitarism and BMI. Total cholesterol, the total to HDL cholesterol ratio, and triglycerides were higher in hypopituitary patients, but only triglycerides and the total to HDL cholesterol ratio depended on hypopituitarism when controlling for BMI. There was no significant difference in lipoprotein(a) levels between hypopituitary women and control subjects. However, when controlling for estrogen use, lipoprotein(a) levels showed a trend toward being lower in the hypopituitary group (P = 0.075). In patients with hypopituitarism, CRP correlated negatively with IGF-I (r = -0.35; P = 0.010), total T (r = -0.42; P = 0.0020), and free T (r = -0.30; P = 0.031). Similarly, IL-6 correlated negatively with total T (r = -0.39; P = 0.0040) and androstenedione (r = -0.27; P = 0.048) in hypopituitary patients. In conclusion, hypopituitary women have increased levels of IL-6 and CRP, both of which are inflammatory markers of atherosclerosis. GH deficiency and androgen deficiency may contribute to these findings. Chronic inflammation may contribute to the high cardiovascular risk seen in this population.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11739438     DOI: 10.1210/jcem.86.12.8087

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  17 in total

1.  Effects of growth hormone deficiency on body composition and biomarkers of cardiovascular risk after definitive therapy for acromegaly.

Authors:  E Lin; T L Wexler; L Nachtigall; N Tritos; B Swearingen; L Hemphill; J Loeffler; B M K Biller; A Klibanski; K K Miller
Journal:  Clin Endocrinol (Oxf)       Date:  2012-09       Impact factor: 3.478

2.  Growth hormone deficiency and cardiovascular risk: do we need additional markers?

Authors:  M Gola; A Giustina
Journal:  Endocrine       Date:  2012-10       Impact factor: 3.633

Review 3.  Disruption of fetal hormonal programming (prenatal stress) implicates shared risk for sex differences in depression and cardiovascular disease.

Authors:  J M Goldstein; R J Handa; S A Tobet
Journal:  Front Neuroendocrinol       Date:  2013-12-16       Impact factor: 8.606

4.  Sex differences in the prevalence of metabolic syndrome and its components in hypopituitary patients: comparison with an age- and sex-matched nationwide control group.

Authors:  Ah Reum Khang; Eu Jeong Ku; Ye An Kim; Eun Roh; Jae Hyun Bae; Tae Jung Oh; Sang Wan Kim; Chan Soo Shin; Seong Yeon Kim; Jung Hee Kim
Journal:  Pituitary       Date:  2016-12       Impact factor: 4.107

5.  Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study.

Authors:  Catherine Beauregard; Andrea L Utz; Amber E Schaub; Lisa Nachtigall; Beverly M K Biller; Karen K Miller; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2008-04-01       Impact factor: 5.958

6.  Reduced growth hormone secretion is associated with increased carotid intima-media thickness in obesity.

Authors:  Hideo Makimura; Takara Stanley; David Mun; Cindy Chen; Jeffrey Wei; Jean M Connelly; Linda C Hemphill; Steven K Grinspoon
Journal:  J Clin Endocrinol Metab       Date:  2009-10-16       Impact factor: 5.958

7.  Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study.

Authors:  Jason Reingold; Christine Wanke; Donald Kotler; Cora Lewis; Russell Tracy; Steven Heymsfield; Phyllis Tien; Peter Bacchetti; Rebecca Scherzer; Carl Grunfeld; Michael Shlipak
Journal:  J Acquir Immune Defic Syndr       Date:  2008-06-01       Impact factor: 3.731

8.  Growth hormone deficiency by growth hormone releasing hormone-arginine testing criteria predicts increased cardiovascular risk markers in normal young overweight and obese women.

Authors:  Andrea L Utz; Ami Yamamoto; Linda Hemphill; Karen K Miller
Journal:  J Clin Endocrinol Metab       Date:  2008-04-29       Impact factor: 5.958

9.  Determination of oxidative protein and lipid damage in adult hypopituitary patients with GH deficiency.

Authors:  N Ozbey; A Telci; U Cakatay; A Yurci; S Molvalilar
Journal:  J Endocrinol Invest       Date:  2003-10       Impact factor: 4.256

10.  Insulin resistance, metabolic syndrome and chronic low grade inflammation in Sheehan's syndrome on standard replacement therapy: a case control study.

Authors:  Manzoor Ahmad Bhat; Bashir Ahmad Laway; Zaffar Amin Shah; Arshad Iqbal Wani; Idrees Mubarik
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.